James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Best ETFs for 2019: The Powershares Water Resource ETF Is Steamin’

The Powershares Water Resource Portfolio is still one of the best ETFs to own until the end of 2019, and beyond.

Don’t Ignore the Johnson and Johnson Pharmaceutical Pipeline

Johnson and Johnson has a rather healthy drug menu with some heavy-hitters about to be added to it. But investors haven't bothered to notice.

3 Big Stock Charts for Thursday: Oracle, KeyCorp and Union Pacific

The stock charts of ORCL, UNP and KEY have taken on technical shapes that merit closer inspection. Here's what you need to know.

3 Big Stock Charts for Wednesday: Walt Disney, Mastercard and Starbucks

The stock charts of DIS, SBUX and MA are moving into pivotal technical situations at the trading week's midpoint.

Square Stock Is Much Better Than the Current Selloff Suggests

The weakness in SQ stock needs to run the rest of its course, and that's when you'll want to step into a new Square position.

3 Big Stock Charts for Tuesday: Baker Hughes, Gilead Sciences and Jefferies Financial Group

The stock charts of GILD, JEF and BHGE earned a closer technical inspection headed into this morning's session.

Too Much Attention from Lawmakers Can Only Hurt Facebook Stock

FB stock will remain uncomfortably vulnerable to regulation as long as Facebook CEO Mark Zuckerberg continues to draw attention to its problems.

New CEO Heyward Donigan Needs a Miracle to Revive Rite Aid Stock

RAD stock looks tempting here in the midst of this lull, but what Rite Aid needs to do the most is the one thing that will be toughest to do.

3 Big Stock Charts for Monday: MSCI, Macerich and Abbott Laboratories

The stock charts of MAC, ABT and MSCI are positioned to start the new trading week in clearly defined situations. Here are levels to watch.

JD.Com Is Fine, but JD Stock Needs a Poke

If JD.com stock has disappointed you, don't throw in the towel just yet. One decent nudge could kickstart a breakout, and then fuel a clear change in opinions of the company's future.